These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15488552)

  • 21. [FDG-PET (positron emission tomography) in the detection of primary breast cancer and lymph node involvement].
    Koga S; Nakano S; Honma Y; Ogasawara N
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():379-84. PubMed ID: 17682181
    [No Abstract]   [Full Text] [Related]  

  • 22. [Fluorine-18 in radiopharmacy].
    de Beco V; Le Bars D; Scherrmann JM
    Ann Pharm Fr; 2008 Jan; 66(1):60-5. PubMed ID: 18435989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positron emission tomography and brain tumours.
    Goldman S; Wikler D; Damhaut P; Monclus M; Levivier M; Pirotte B; De Witte O; Brotchi J; Hildebrand J
    Acta Neurol Belg; 1997 Sep; 97(3):183-6. PubMed ID: 9345590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Early prediction of response to primary chemotherapy by sequential FDG -PET in patients with advanced breast cancer].
    Momiyama N; Ishikawa T; Ichikawa Y; Shimada H; Katayama A; Ozawa Y
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():385-8. PubMed ID: 17679210
    [No Abstract]   [Full Text] [Related]  

  • 25. F-18 FDG PET imaging in a primitive neuroectodermal tumor.
    Watanabe N; Kawano M; Takada M; Iwamoto S; Shimizu M; Kawabe H; Kamisaki Y; Noguchi K; Seto H
    Clin Nucl Med; 2006 Aug; 31(8):484-5. PubMed ID: 16855439
    [No Abstract]   [Full Text] [Related]  

  • 26. [Possibilities of using molecular imaging methods with complex modern radiopharmaceuticals in neurooncology].
    Tiutin LA; Stanzhevskiĭ AA; Panfilenko AF; Kostenikov NA; Iliushchenko IuR
    Vopr Onkol; 2013; 59(4):421-7. PubMed ID: 24032214
    [No Abstract]   [Full Text] [Related]  

  • 27. [Development trend of PET radiopharmaceuticals as post-FDG tumor imaging agents].
    Kawai K
    Nihon Hoshasen Gijutsu Gakkai Zasshi; 2006 Jun; 62(6):764-70. PubMed ID: 16856253
    [No Abstract]   [Full Text] [Related]  

  • 28. Simultaneous demonstration of metabolic lesions consistent with Alzheimer disease and brain metastases on FDG-PET imaging.
    Takalkar AM; El-Haddad G; Lilien DL; Patterson JC
    Clin Nucl Med; 2008 Jun; 33(6):438-40. PubMed ID: 18496460
    [No Abstract]   [Full Text] [Related]  

  • 29. [Whole body positron emission tomography (PET) with (18F)-fluorodeoxyglucose].
    Grupo PET de la SEMN
    Rev Esp Med Nucl; 2002 Apr; 21(2):128-30. PubMed ID: 11879625
    [No Abstract]   [Full Text] [Related]  

  • 30. A brief history of positron emission tomography (PET).
    Wagner HN
    Semin Nucl Med; 1998 Jul; 28(3):213-20. PubMed ID: 9704363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures.
    Pirotte B; Goldman S; Dewitte O; Massager N; Wikler D; Lefranc F; Ben Taib NO; Rorive S; David P; Brotchi J; Levivier M
    J Neurosurg; 2006 Feb; 104(2):238-53. PubMed ID: 16509498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain abnormalities detected on whole-body 18F-FDG PET in cancer patients: spectrum of findings.
    Stubbs E; Kraas J; Morton KA; Clark PB
    AJR Am J Roentgenol; 2007 Mar; 188(3):866-73. PubMed ID: 17312080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine.
    Kaschten B; Stevenaert A; Sadzot B; Deprez M; Degueldre C; Del Fiore G; Luxen A; Reznik M
    J Nucl Med; 1998 May; 39(5):778-85. PubMed ID: 9591574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
    Vallabhajosula S
    Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Abnormal fluorine-18 fluorodeoxy-glucose uptakes in the aorta and subclavian artery of a 66-year-old woman].
    Taniguchi H; Momiyama Y; Kihara T; Nagata M; Ohsuzu F
    J Cardiol; 2004 Sep; 44(3):123-5. PubMed ID: 15500163
    [No Abstract]   [Full Text] [Related]  

  • 36. Injected dose in pediatric PET.
    Watson CC
    J Nucl Med; 2010 Oct; 51(10):1657; author reply 1657-8. PubMed ID: 20847164
    [No Abstract]   [Full Text] [Related]  

  • 37. Fluorine-18 fluorodeoxyglucose PET/CT is a suitable instrument to show the effects of lipid metabolism disorders on metabolic networks in the living organism.
    Kulterer OC; Hacker M
    J Nucl Cardiol; 2022 Jun; 29(3):1415-1418. PubMed ID: 33629248
    [No Abstract]   [Full Text] [Related]  

  • 38. Increased fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion.
    Borgwardt L; Højgaard L; Carstensen H; Laursen H; Nowak M; Thomsen C; Schmiegelow K
    J Clin Oncol; 2005 May; 23(13):3030-7. PubMed ID: 15860860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SUV: from silly useless value to smart uptake value.
    Visser EP; Boerman OC; Oyen WJ
    J Nucl Med; 2010 Feb; 51(2):173-5. PubMed ID: 20080897
    [No Abstract]   [Full Text] [Related]  

  • 40. Would patient selection based on both calcitonin blood level and doubling time improve 18F-FDG PET sensitivity in restaging of medullary thyroid cancer?
    Aide N; Bardet S
    J Nucl Med; 2007 Sep; 48(9):1574; author reply 1574-5. PubMed ID: 17785732
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.